Intramuscular progesterone (Gestone) versus vaginal progesterone suppository (Cyclogest) for luteal phase support in cycles of in vitro fertilization–embryo transfer: patient preference and drug efficacy

Amal Yaseen Zaman 1, Serdar Coskun 2, Ahmed Abdullah Alsanie 3 and Khalid Arab Awartani 2*

Abstract

Background: The requirement for luteal phase support (LPS) in stimulated IVF cycles is well established, however drug choice, and route of administration and duration of use are not. This report evaluates patients’ preference and satisfaction by using either vaginal or intramuscular (IM) progesterone (P) supplementation for luteal phase support after in vitro fertilization and embryo transfer (IVF-ET).

Methods: It is a prospective cohort study done in a reproductive and infertility unit in a tertiary care hospital from March 2013 through February 2015 for four hundred and nine patients undergoing IVF-ET. Patients were allowed to choose either vaginal or IM P for LPS. Patient preference and satisfaction, as well as differences in clinical pregnancy rates between the two groups were assessed at one or two time points throughout the study.

Results: There were no statistically significant differences in the patients’ characteristics and clinical outcomes between the two groups. There were 88 pregnancies (38.8%) among patients treated with vaginal P and 62 pregnancies (34%) among IM P patients. Average satisfaction score at the pregnancy test and ultrasound (U/S) visits was similar between both groups.

Conclusions: Patients’ satisfaction and pregnancy rates were similar between vaginal and IM P supplementation.

Keywords: Vaginal, Intramuscular, Progesterone, Luteal phase support, In vitro fertilization, Pregnancy rate

Background

The requirement for luteal phase support (LPS) in stimulated IVF cycles is well established, however drug choice, route of administration and duration of use are not [1]. American Society for Reproductive Medicine (ASRM) Position Statement asserts that, “based on available data, progesterone supplementation in IVF cycles yields significantly higher pregnancy rates compared with placebo or no treatment and lower risks for ovarian hyper stimulation syndrome compared with supplementation with human chorionic gonadotropin (hCG)” [2].

A recent Cochrane meta-analysis discussing luteal phase support for ART cycles confirmed that P has a significantly positive effect on clinical pregnancy, live birth and on-going pregnancy rates [3]. The pharmacological properties are different according to the route of P administration. It has been reported that IM administration of P results in rapid absorption with higher serum P concentrations [4]. Moreover, IM P has a longer half-life and longer therapeutic levels compared to vaginal route allowing a wider implantation window and less endometrial contractions on the day of the embryo transfer.
Methods
Study design
This is a prospective cohort study that included a group of 409 women who underwent IVF-ET treatment at KFSH& RC IVF unit from March 2013 through February 2015. Each woman completed a fresh treatment cycle of IVF-ET, using her own oocytes. On the day of embryo transfer patients were offered to choose between vaginal or IM P for LPS. The study was explained to the patients and they were asked to participate. Patients who agreed to partake in the study were asked to sign an informed consent form and their choice of drug was prescribed. Cyclogest vaginal P used at a dose of 400 mg twice daily (L.D. Collin, Barnstable, UK) and 50 mg IM Gestone (Ferring Pharmaceutical, Parsippany, NJ, USA).

In both groups, P luteal phase support started on the day of embryo transfer and continued until a negative pregnancy test was confirmed, pregnancy loss occurred, or up to 10 weeks gestation was achieved (ongoing pregnancy). During their second visit for pregnancy test, they were interviewed to fill the satisfaction questionnaire and blood collected for β-hCG. If not pregnant, treatment and study will be terminated after we phone interview the woman. If pregnant, the patient was given a pregnancy ultrasound appointment after 5 weeks according to the IVF Clinic protocol. On their 3rd visit for pregnancy ultrasound, patients were again interviewed to fill the satisfaction questionnaire for second and last time.

The study was conducted in accordance with the ethical principles of King Faisal Specialist Hospital and Research Center ethical committees. The protocol and its associated Informed Consent Agreement were reviewed and approved by the appropriate Institution committee. Study personnel obtained written informed consent directly from all participants before their entry into the study.

Inclusion criteria
Healthy women between 18 and 40 years of age, with a body mass index ≤34 kg/m², a baseline FSH level ≤ 12 mIU/mL on day 3 of menstrual period, a history of infertility or genetic disease requiring IVF or Pre-implantation Genetic Diagnosis (PGD) and a normal uterine cavity were included in the study.

Treatment protocol
Patients underwent pituitary down-regulation either with GnRH agonist or GnRH antagonist protocol. In GnRH agonist protocol one dose of Leupron depot 3.75 mg IM injection administered during the follicular phase between cycle day (CD) 2 and CD5. Documentation of the down-regulation of the pituitary and ovaries was confirmed by endometrial lining <5 mm and no evidence of ovarian cysts on the transvaginal (TV) U/S. Ovarian cysts were defined as ovarian follicles with a mean diameter ≥ 15 mm). Starting stimulation and following the response depend on TV U/S; estradiol levels were not measured. After documentation of adequate down-regulation of the pituitary/ovarian axis, gonadotropin treatment was started with the use of hMG (Menogon; Ferring Pharmaceuticals, Parsippany, NJ) or recombinant FSH (Gonal F, Merck Pharmaceuticals, Whitehouse Station, NJ, USA). In GnRH antagonist protocol Genarlix (Merck Pharmaceuticals, Whitehouse Station, NJ, USA) 0.5 mg SC started on day 7 of stimulation (fixed antagonist protocol). All women received at least one vial of hMG daily during the period of COH. Ovulation was triggered by administration of 5000 IU or 10,000 IU hCG when three or more follicles had reached a diameter of 18 mm or greater. Oocytes were retrieved 36 h later using single lumen needle without flushing the follicles. Eggs were inseminated either by conventional IVF or by intracytoplasmic sperm injection as appropriate. A maximum of two cleavage stage or two blastocyst stage embryos were transferred on either post retrieval day 3, or days 5, depending on the quality and quantity of embryos available. About 2 weeks after ET, a serum pregnancy test was performed to document biochemical pregnancy. If positive, a repeat serum pregnancy test was performed after 2 days. At about 3 weeks after a positive serum pregnancy test, clinical pregnancy was confirmed by TV U/S. The women who were pregnant continued taking P support until 10 weeks gestational age.
Assessments

During each visit (i.e., on ET day, on hCG pregnancy test day and on U/S pregnancy confirmation visit at 7 weeks of gestation, some recurrent pregnancy loss patients were scheduled for TV U/S as early as 5 weeks plus, patients were asked by the study investigator to assess their overall health and fill the satisfaction questionnaire. A satisfaction score from 1 to 5 (5 is a high score and 1 is a low score) was used to assess patients’ satisfaction in regard to treatment methods. Responses to the survey assessed compliance and ease of use and other variables such as pain and discomfort associated with the studied drug administration. Assessment of safety and tolerability included documentation of side effects (SE) which is an unpleasant effect of a drug that happens in addition to the main effect (Table 1).

Outcomes

The primary outcome was the percentage of patients preferring IM P as route of administration for LPS during IVF-ET cycles compared to the percentage of vaginal supplementation and their satisfaction with their choice. The secondary efficacy variables were positive β-hCG test rate, clinical pregnancy rate and early spontaneous abortion rate in both groups.

Clinical pregnancy was defined as the presence of one or more gestational sacs detected on ultrasound scan performed 5 weeks after embryo transfer. Biochemical pregnancy loss was defined as a rise in the β-hCG with no evidence of any gestational sac on the ultrasound scan. Miscarriage was defined as a pregnancy loss after U/S confirmation of a positive fetal heart embryo and before 12 weeks gestation.

Table 1: The questions asked to the patients during their initial, pregnancy test day and U/S day visits

| 1st Visit (ET day) | 2nd Visit (Preg. test day) | 3rd Visit (U/S day, 7 wks. Preg.) |
|-------------------|---------------------------|----------------------------------|
| AGE               |                           |                                  |
| BMI               |                           |                                  |
| Endometrial Thickness- |                        |                                  |
| Infertility type  |                           |                                  |
| - 1ry             |                           |                                  |
| - 2ry             |                           |                                  |
| Duration of infertility |                     |                                  |
| Menstrual pattern |                           |                                  |
| - regular         |                           |                                  |
| - irregular       |                           |                                  |
| Infertility factor|                           |                                  |
| - anovulation     |                           |                                  |
| - endometriosis   |                           |                                  |
| - male factor     |                           |                                  |
| - tubal factor    |                           |                                  |
| - other           |                           |                                  |
| Type of cycle:    |                           |                                  |
| IVF               |                           |                                  |
| ICSI              |                           |                                  |
| IVF/ICSI          |                           |                                  |
| Patient choice:   |                           |                                  |
| - Cyclogest       |                           |                                  |
| - Gestone         |                           |                                  |
| - Pregnancy test: |                           |                                  |
| - ve              |                           |                                  |
| + ve              |                           |                                  |
| - Was the type of progesterone changed? |                   |                                  |
| YES               |                           |                                  |
| NO                |                           |                                  |
| - Side effects:   |                           |                                  |
| Perineal irritation|                         |                                  |
| Rectal itching    |                           |                                  |
| Vaginal bleeding  |                           |                                  |
| Vaginal or rectal leaking or discharge |             |                                  |
| Constipation      |                           |                                  |
| Discomfort after administration |           |                                  |
| Hematoma formation|                         |                                  |
| Other             |                           |                                  |
| - Patient’s compliance: |                     |                                  |
| - Patients satisfaction: |                   |                                  |
|YES                |                           |                                  |
|NO                 |                           |                                  |
| - Pregnancy outcome: |                         |                                  |
| Biochemical       |                           |                                  |
| Clinical          |                           |                                  |
The expected side effects of IM P i.e. discomfort after administration, hematoma formation and vaginal bleeding) or vaginal P treatment (perineal irritation, inflammation, itching, vaginal or rectal leakage or bleeding), as well as the systemic side effects (e.g. constipation and abdominal pain) were of particular interest.

Statistics
Comparison of the two groups in terms of demographic and cycle characteristics (age, BMI, duration of infertility and number of IVF cycle) were done by using two independent sample t-test. For categorical values (male factor infertility, positive pregnancy test, pregnancy loss and SEs) we used chi-square test. Mean, median, range and standard deviation (SD) were used as descriptive statistics. Mann-Whitney non-parametric test was used to compare between median score of the two drugs because we are making comparison of two drugs preparation in two occasions (visit). The problem of multiplicity was avoided using Bonferroni correction with a P-value to be significant if it falls below 0.025 (0.05/2 = 0.025).

Results
A total of 409 patients were involved in the study, 227 in the vaginal group and 182 in the IM group; all of them agreed to participate. All were approached either during their routine visits (ET, pregnancy test and U/S day) or through phone interview. 61.2% of the vaginal group completed the ET and pregnancy test visits and the remaining 38.8% became pregnant and all of them completed the whole three follow-up visits (no one lost to follow-up). Similarly, in the IM group 66% completed two follow-up visits and 34% became pregnant and completed the three visits and none were lost to follow-up.

(Table 2) shows demographic and cycle characteristics in the vaginal and IM groups. The two groups were without significant differences in age, BMI or cycle characteristics (number of prior cycles and type of stimulation protocol and endometrial thickness on hCG day as well as the duration of infertility was similar for the vaginal and IM P treatment groups (Table 2). Similarly, there was no significant difference between the two groups with regard to treatment outcomes including rates of positive pregnancy tests and pregnancy loss (Table 3). Male factor infertility consider the only infertility diagnosis differing substantially with P-value = 0.03 (Table 4).

There were significant differences between the two groups regarding the side effects. Discomfort after administration was the common side effect reported with IM P. Vaginal leak and rectal leak are the most common SEs with the vaginal group (Table 5). Moreover, vaginal group has significantly more rectal itching and constipation and IM group had three hematoma formation which had borderline significance P value = 0.05. Satisfactions were similar and not statistically different between both groups in pregnancy and U/S visits (Table 6).

Discussion
This analysis provides a, prospective comparison of patient-reported compliance and overall patient satisfaction for vaginal P compared to IM P from a population of women undergoing IVF. The most distinguishing result in this study was the selection of IM route (their own choice) by a good number of patients although they were given information about similar efficacy and outcome for both routes. This might be due to cultural sensitivity regarding use of vaginal route despite pain and discomfort after administration of IM P.

There are limited studies, evaluating administration preferences for different P routes for luteal phase support. One study compared P vaginal inserts (endometrin) to IM P [10], preferences following provider randomization at the start of their luteal phase and at their final visit Patients’ convenience, ease of use lead to higher patient satisfaction with the vaginal route compared to the IM route (82.6% of patients in vaginal group compared with 44.9% in IM group). In our study, patients were given the choice to select their preferred route of progesterone administration on the ET day. 55.5% of patients preferred the vaginal route and the other 44.5% preferred the IM route.

Only a few studies about P for luteal phase support have attempted to assess patients’ treatment satisfaction and ease of use. Previous studies reported better satisfaction with vaginal gel and vaginal insert than IM P [10–12]. Another study assessed the women’s satisfaction with weekly P vaginal ring (VR) versus 8% P gel for luteal phase support after IVF it confirmed that VR was more convenient, less

Table 2 Demographic features and cycle characteristics

|                          | Vaginal (n = 227) | IM (n = 182) | P value |
|--------------------------|-------------------|-------------|---------|
| Age (MEAN and SD)        | 31.3 ± 4.7        | 31.6 ± 5    | 0.5     |
| BMI (MEAN and SD)        | 28.6 ± 4          | 27.9 ± 4.3  | 0.2     |
| Duration of infertility(MEAN and SD) | 6 ± 4          | 6 ± 4      | 0.35    |
| NO. of cycle (MEAN and SD)| 2 ± 1.7        | 2 ± 1.5     | 0.84    |
| Long protocol n (%)      | 152 (67%)         | 110 (60%)   | 0.067   |
| GnRH Antagonist n (%)    | 75 (33%)          | 72 (40%)    | 0.3     |

*Chi-square test was used

Table 3 Cycle outcome

| Cycle outcome | Vaginal (n = 227) | IM (n = 182) | P value |
|---------------|-------------------|-------------|---------|
| +ve PREG. TEST n (%) | 88 (38.8%) | 62 (34%) | 0.9 |
| Pregnancy loss n (%)   | 15 (17%)         | 11 (17.7%)  | 0.9    |

*Chi-square test was used
stressful and associated with less leakage than the gel [12]. In our study, patients’ satisfaction with their choice was assessed by using satisfaction questionnaire with scale from one to five (one is least satisfied and five is most satisfied) which showed no significant difference between the groups. Although a significant number of patients had pain and discomfort after administering the IM P it didn’t affect their compliance and satisfaction towards their choice, and all of the patients continued the treatment period with the same drug although they had the option of changing it. Comparing our results to previous studies that confirmed worldwide preference of vaginal route with suppositories, gel or inserts are more commonly desired than the IM route. This suggests that the vaginal route provides an easy-to-use and convenient method without pain and discomfort following administration as compared to the IM route [10, 12–14]. Our study may differ from other published reports due to cultural difference in our population. We believed that cultural differences contributed to our results in our population since vaginal and rectal leakage might interfere with a woman’s daily religious prayers.

Pregnancy outcome including clinical pregnancy and miscarriage rates were assessed in a previous study and

Table 4 Infertility diagnosis<sup>a</sup>

| Primary Cause of inf. | Vaginal (n = 227) | IM (n = 182) | P value |
|-----------------------|------------------|------------|---------|
| Anovulation n (%)     | 20 (9%)          | 13 (7%)    | 0.5     |
| Male factor n (%)     | 125 (55%)        | 119 (65%)  | 0.03    |
| Pelvic and peritoneal factor n (%) | 19 (8.3%) | 12 (7%) | 0.5 |
| Unexplained n (%)     | 18 (8%)          | 17 (9%)    | 0.6     |
| Other n (%)           | 45 (19.7%)       | 21 (12%)   | 0.02    |

<sup>a</sup> Chi-square test was used

Table 5 Overall side effects for each treatment in pregnancy test and U/S visit<sup>a</sup>

| Side effect                                      | Vaginal (n = 227) | IM (n = 182) | P value |
|--------------------------------------------------|------------------|------------|---------|
| Any side effect n (%)                            | 76 (33.5%)       | 53 (29%)   | 0.3     |
| Perineal irritation n (%)                        | 7 (3%)           | 3 (1.6%)   | 0.3     |
| Rectal itching n (%)                            | 12 (5%)          | 1 (0.5%)   | 0.006   |
| Vaginal bleeding n (%)                          | 10 (4.4%)        | 4 (2.2%)   | 0.2     |
| Rectal leak n (%)                               | 22 (9.7%)        | 0          | 0.00016 |
| Vaginal leak n (%)                              | 35 (15.4%)       | 2 (1.1%)   | <0.0001 |
| Constipation n (%)                              | 22 (9.7%)        | 4 (2.2%)   | 0.002   |
| Discomfort after administration n (%)           | 3 (1.3%)         | 33 (18%)   | <0.0001 |
| Abdominal pain n (%)                            | 3 (1.3%)         | 1 (0.5%)   | 0.4     |
| Diarrhea n (%)                                  | 1 (0.4%)         | 0          | 0.4     |
| Bloating n (%)                                  | 1 (0.4%)         | 0          | 0.4     |
| Hematoma formation n (%)                        | 0                | 3 (1.65%)  | 0.05    |

<sup>a</sup> Chi-square test was used

found no statistically significant differences among both treatment groups [10, 12, 14–19]. Pregnancy outcomes in this study were similar to those reported in previous studies.

Regarding side effects, discomfort after administration has been reported frequently with IM P which is the most common SE reported with this route in all previous studies [10–13] as well as in this study. For the vaginal route, vaginal leakage and rectal leakage are the most common SEs reported during our study. These described undesirable events are expected and specific to each route. A new route of P administration by aqueous subcutaneous P h shows different pharmacokinetic parameters and lower dosing is needed. This may result in fewer side effects, mainly pain and discomfort after administration. Two large multicenter RCTs demonstrated that the subcutaneous P 25 mg administered once daily is effective and more convenient to the patient [20–22]. It may be suitable for women who prefer to avoid the IM and vaginal routes of administration [20–22]. This drug should be to be tested in Saudi population once it is available.

Conclusions

Patients’ satisfaction and pregnancy rates were similar between use of vaginal and IMP.

Abbreviations

ART: Assisted reproductive technology; BMI: Body mass index; CD: Cycle day; E2: Serum estradiol; ET: Embryo transfer/U/S/ultrasound; FSH: Follicle-stimulating hormone; GnRH: Gonadotropin-releasing hormone; GnRHa: Gonadotropin-releasing hormone agonist; HCG: Human chorionic gonadotropin; IM: Intramuscular; IVF: In vitro fertilization; LPS: Luteal phase support; OHSS: Ovarian hyperstimulation syndrome; P: Progesterone; PCOS: Polycystic ovarian syndrome; PGD: Preimplantation genetic diagnosis; PIO: Progesterone in oil; Preg: Pregnancy; Pt: Patient; rFSH: Recombinant FSH; SC: Subcutaneously; SD: Standard deviation; U/S: Ultrasound; FSH: Follicle-stimulating hormone; GnRHa: Gonadotropin-releasing hormone agonist; HCG: Human chorionic gonadotropin; IM: Intramuscular; IVF: In vitro fertilization; LPS: Luteal phase support; OHSS: Ovarian hyperstimulation syndrome; P: Progesterone; PCOS: Polycystic ovarian syndrome; PGD: Preimplantation genetic diagnosis;PIO: Progesterone in oil; Preg: Pregnancy; Pt: Patient; rFSH: Recombinant FSH; SC: Subcutaneously; SD: Standard deviation; U/S: Ultrasound.

Acknowledgements

We like to thank Miss Salma Al Otaibi, IVF coordinator and all IVF clinical staff members for their help and support during the study.

Funding

None.

Availability of data and materials

The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

Authors’ contributions

AYZ contributed to the design of the study, collection and interpreted the data and participated in writing of the manuscript. SC and AAS contributed to the design of the study and revision of the manuscript. KAA contributed to conception and design of the study and interpreted the data. KAA and SC
read and gave final approval for the version submitted for publication. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Research ethics committee of King Faisal Specialist Hospital and Research Center approved the study (RAC2131013). The protocol and its associated Informed Consent Agreement were reviewed and approved by the appropriate Institution committees.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1. King Faisal Specialist Hospital and Research Center and Taibah University, Al Maather, Riyadh 12713, Saudi Arabia. 2. King Faisal Specialist Hospital Research Center and Al Faissal University, Al Maather, Riyadh 12713, Saudi Arabia. 3. King Faisal Specialist Hospital and Research Center and Alfaisal University, Al Maather, Riyadh 12713, Saudi Arabia. 4. Private Practice, Alkhobar, Saudi Arabia.

Received: 28 May 2017 Accepted: 25 October 2017
Published online: 09 November 2017

References
1. Lockwood G, Griesinger G, Cometti B. Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a non-inferiority randomized controlled study. Fertil Steril. 2014;101:112–9.
2. ASRM Practice Committee. Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin. ASRM practice committee position statement. Fertil Steril. 2008;90:S150–3.
3. Van der Linden M, Buckingham K, Farquhar C, Kremer IAM, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2015;7:CD009154.
4. Cicinelli E, de Ziegler D, Bulet G, Matteo MG, Schonauer LM, Galantino P. Direct transport of progesterone from vagina to uterus. Obstet Gynecol. 2000;95:403–6.
5. Casper RF. Luteal phase support for frozen embryo transfer cycles: intramuscular or vaginal progesterone? Fertil Steril. 2012;101:627–8.
6. Zaman et al. Fertility Research and Practice (2017) 3:17
7. Zarutskie PW, Phillips JA. A meta-analysis of the route of administration of progesterone for luteal phase support in assisted reproductive technology: vaginal versus intramuscular progesterone. Cochrane Database Syst Rev. 2015;7:CD009154.
8. Palomba S, Santagni S, Battista La Sala G. Progesterone administration for luteal phase deficiency in human reproduction: an old or new issue? Review. Journal of Ovarian Research. 2015;8:77.
9. Zarutskie PW, Phillips JA. A meta-analysis of the route of administration of luteal phase support in assisted reproductive technology: vaginal versus intramuscular progesterone. Fertil Steril. 2009;92:163–9.
10. Doody K, Bush M, Collins M. Progesterone supplementation for luteal support: efficacy and patient experience with vaginal inserts (Endometrin) versus intramuscular injection. Fertil Steril. 2012;97:25.
11. Yanushpolsky E, Hunzvit S, Greenberg L, Racovsky C, Hornstein MD. Crinone vaginal gel is equal to, and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization-embryo transfer cycles: a prospective randomized study. Fertil Steril. 2010;94:2596–9.
12. Silverberga B, Howard B. Satisfaction with progesterone vaginal ring (PGN VR): study of women participating in a randomized trial of daily use of PGN VR YS vaginal ring gel as luteal support after in vitro fertilization. Fertil Steril. 2012;97:2596–9.
13. Zarutskie PW, Phillips JA. A meta-analysis of the route of administration of luteal phase support in assisted reproductive technology: vaginal versus intramuscular progesterone. Fertil Steril. 2009;92:163–9.
14. Chantilis SJ, Zeitoun KM, Patel SI, Johns DA, Madzhar VE, McIntyre DD. Use of crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles. Fertil Steril. 1999;72:823–9.
15. Dal Prato L, Bianchi L, Cattori M, Tardozzi F, Flamigni C, Borini A. Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reprod BioMed Online. 2008;16:361–7.
16. Jobanputra K, Toner JP, Denoncourt R, Gibbons WE. Crinone 8% (90 mg) given once daily for progesterone replacement therapy in donor egg cycles. Fertil Steril. 1999;72:980–4.
17. Kahraman S, Karagozoglu SH, Karlikaya Y. The efficiency of progesterone vaginal gel versus intramuscular progesterone for luteal phase supplementation in gonadotropin-releasing hormone antagonist cycles: a prospective clinical trial. Fertil Steril. 2010;94:761–3.
18. Khan N, Richter KS, Newcombe TL, Blake EJ, Yankov V. Matched samples comparison of intramuscular versus vaginal progesterone for luteal phase support after in vitro fertilization and embryo transfer. Fertil Steril. 2009;91:2445–50.
19. Baker VL, Jones CA, Doody K, Foulk R, Yee B, Adamson GD, et al. A randomized controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization. Hum Reprod. 2014;29:2212–20.
20. Ziegler D. A randomized trial comparing the endometrial effects of daily subcutaneous administration of 25 mg and 50 mg of progesterone in aqueous preparation. Fertil Steril. 2013;100:860–6.
21. Sator M, Radicori M, Corretti B, Lopreste L, Levratti C, Schmid D, et al. Pharmacokinetics and safety profile of a novel progesterone aqueous formulation administered by the s.C. Route. Gynecol Endocrinol. 2013;29:205–8.